<DOC>
	<DOC>NCT00653822</DOC>
	<brief_summary>The objective of this study is to compare the pharmacokinetic and pharmacodynamic properties and safety profile of alefacept in Caucasian and Japanese healthy subjects</brief_summary>
	<brief_title>A Study of Pharmacokinetics and Safety of Alefacept in Caucasian and Japanese Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Alefacept</mesh_term>
	<criteria>Caucasian or Japanese healthy subject with a body mass index (BMI) of 18 to 29 kg/m2, inclusive Japanese subject is first generation, born in Japan from parents of Japanese decent, and has resided outside of Japan for 5 years or less OR Caucasian subject is Hispanic or nonHispanic, born of parents of European decent (not Mestizo or mixed race) Subject must have clinical laboratory test results within the normal therapeutic range or, if abnormal, the results are not clinically significant as determined by the investigator CD4+ lymphocyte count outside normal limits at Screening Received vaccine within 60 days prior to study drug administration History of drug or alcohol abuse within the 2 years prior to the study drug administration Treatment with any systemic immunosuppressant agent within 6 months prior to study drug administration Treatment with any antibody or biologic product within 6 months prior to study drug administration Treatment with any systemic steroid or steroid inhaler within 2 months prior to study drug administration A smoking habit of greater than 10 cigarettes a day</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Amevive</keyword>
	<keyword>alefacept</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Japanese</keyword>
</DOC>